Research and Markets: Innovation, Health Technology Assessment, and Comparative Effectiveness Research: the Obstacle Course to Market Access
DUBLIN--(Business Wire)-- Research and Markets (http://www.researchandmarkets.com/research/5df5d2/innovation_health) has announced the addition of Decision Resources, Inc.'s new report "Innovation, Health Technology Assessment, and Comparative Effectiveness Research: The Obstacle Course to Market Access" to their offering. The use of health technology assessment (HTA) is growing steadily in Europe, and the U.S. government has recently announced $1.1 billion in funding for comparative effectiveness research (CER) as part of its planned overhaul of the U.S. healthcare system. Payers in all markets will increasingly compare new drugs with established therapies and offer the most favorable pricing and reimbursement terms only to drugs that are deemed innovative. Questions Answered in This Report: HTA has become a major focus of attention in healthcare systems around the world in recent years. * What are the key elements of HTA? * What approaches have the authorities in leading pharmaceutical markets taken to the use of HTA? European governments have used various forms of HTA for many years. * How do HTA strategies vary from one European country to another? * What common trends can be observed in Europe? The United States has been much slower than other mature pharmaceutical markets to embrace HTA. * Which U.S. organizations have practiced HTA in the past? * What action has the U.S. government recently taken to stimulate greater use of CER in the United States? Scope: * Increasing focus on HTA: definitions of HTA; role of health economic evaluation; strategies in major markets. * Use of HTA in leading markets: France; Germany; Italy; Spain; United Kingdom; United States; international collaborations. * Outlook and implications for the pharmaceutical industry: European industry's key principles for HTA; challenges presented by the adoption of CER in the United States; key message to payers. Key Topics Covered: Executive Summary * Strategic Considerations * Stakeholder Implications The Challenge of Assessing Innovation France * HTA as an Element of the Standard Price-Setting Process * HTA as an Element of the Price-Setting Process for Innovative Drugs * Multiple Technology Assessments * National Frame of Reference for the Appropriate Use of Expensive and Innovative Drugs * Expanded Role for the National Health Authority * Pending Reforms Germany * Coverage Offered by the Statutory Health Insurance System * Introduction of Health Economic Evaluation * Regulatory Framework * Opposition from Health Economists and the Pharmaceutical Industry * Response of the GBA and IQWiG to Criticism * Draft Methodology for Health Economic Evaluation * Future Focus on Costly New Therapies * Government Plans for Stricter Limits on Access to Some New Therapies Italy * HTA as an Element of Pricing and Reimbursement Decision Making Spain * Pharmaceutical Price Setting * Progress Toward a National HTA Strategy United Kingdom * - Creation of the National Institute for Health and Clinical Excellence * Industry Criticisms of NICE * Government Response to Parliamentary Review of NICE * New Pharmaceutical Price Regulation Scheme * Horizon Scanning * Guaranteed Funding for NICE-Approved Therapies * Guidance on the Funding of Therapies Not Appraised by NICE * Promoting the Uptake of New Drugs * Flexible Pricing * Patient Access Schemes * Improving Patient Access to Innovative Medicines * Plans for NICE to Offer an Advisory Service to the Pharmaceutical Industry * Risk-Sharing and Cost-Sharing Agreements-Creative Responses to Rejection by NICE * Growing Industry Disillusionment with the U.K. Market United States * Academy of Managed Care Pharmacy's Format for Formulary Submissions * Technology Evaluation Center * Drug Effectiveness Review Project * WellPoint Health Networks * Agency for Healthcare Research and Quality * Medicare * New Government-Sponsored Comparative Effectiveness Research Initiative International Cooperation on Health Technology Assessment Outlook and Implications for the Pharmaceutical Industry For the complete list of over 40 companies mentioned in this report, click the link below http://www.researchandmarkets.com/research/5df5d2/innovation_health Research and Markets Laura Wood, Senior Manager, press@researchandmarkets.com U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Copyright Business Wire 2009
